Patient enrollment remains one of the most critical bottlenecks in global drug development, often delaying timelines, increasing costs, and limiting patient access to innovative therapies. Against this backdrop, China has emerged not merely as a region of vast patient numbers, but as a laboratory for systemic innovation in clinical trial execution. 患者入组仍是全球药物开发中最关键的瓶颈之一，常常导致时间线延误、成本上涨，而且还会限制患者获得创新疗法的机会。在这一背景下，中国利用其庞大的患者数量而，不断发展临床试验执行中的体系创新。
- How China Building Beyond “Population Advantage”
- How to Leverage AI and Digital Platforms in Patient Matching
- The Power of Hospital Alliances and Regional Clinical Hubs
- Aligning Patient Recruitment, Clinical Supply Strategy And Site Readiness To Reduce Delays
- How to Adapt China’s Model for International Multi-Center Trials
- 中国不仅是“人口优势”
- 如何利用 AI 与数字平台进行患者匹配
- 医院联盟与区域临床中心的发展
- 患者招募、临床供应策略的动态调整
- 如何将中国模式应用于MRCT
|
Visit our exhibitors’ booths throughout the day and collect stamps in order to enter our Prize Draw and be in for a chance of winning Apple prizes or Amazon gift cards. The Prize Draw will take place in the Exhibition Hall. Make sure you don’t miss out!
Best 3 LinkedIn posts from day 1 with hashtag #OCT and @Outsourcing in Clinical Trials Event Series tagged will win a prize in day 2 morning’s prize draw during chair’s opening remarks. Deadline end of drinks reception day 1. You must be present to win!
- Why recruitment forecasts and feasibility assessments across the DACH region continue to miss targets despite strong research infrastructure and healthcare systems
- How increasing study competition, protocol complexity, and limited patient availability are placing growing pressure on sites
- The operational challenges impacting recruitment and patient access across the region
- How sponsors, CROs, and sites can work together to create more realistic feasibility strategies and more sustainable approaches to patient recruitment and site engagement
2 seats available for biotech/ pharma
1 seat available for event sponsor
- Exploring how AI can support end-to-end clinical trial delivery, from protocol authoring and risk assessment through to data analysis and reporting
- Examining how historical trial outcomes, regulatory feedback, and operational data can be leveraged to improve planning, country selection, site strategy, and database design
- Understanding how AI-driven connectivity across departments can break down silos and create a more integrated approach to trial execution
- Discussing how organisations can operationalise AI strategically to future-proof clinical development processes rather than applying disconnected point solutions
1 seat available for event sponsor
